Abstract
Treatment of bone metastasis consists of surgical therapy, radiotherapy, and drug therapy. Although the selection of drugs is currently limited, bisphosphonates such as zoledronate improve bone-related events and hypercalcemia, and have a central role in the drug treatment of bone metastasis. In addition, zoledronate seems to have potential anti-tumor effects in a part of bone metastases from several lines of both basic researches and clinical studies, considering a new position of zoledronate in cancer treatment. Recently, denosumab, an anti-RANKL monoclonal antibody, has been approved. Prevention of bone-related events by denosumab is equivalent to or more potent than that by zoledronate for some cancers. However, evidence supporting the effectiveness of these treatment modalities is currently limited. It is necessary to arrive at a consensus the application of different modalities and selection of drugs in the treatment of bone metastasis.
| Original language | English |
|---|---|
| Pages (from-to) | 1169-1173 |
| Number of pages | 5 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 39 |
| Issue number | 8 |
| Publication status | Published - 2012 Aug |
Keywords
- Bone metastasis
- Denosumab
- Zoledronate
ASJC Scopus subject areas
- Oncology
- Cancer Research
